Impact of Japanese drug price reductions, by P Reed Maurer

10 May 2012

Outside observers have long predicted the mandated price reductions of drugs will kill the Japanese pharmaceutical industry, reduce the motivation to introduce new drugs, and stifle innovation, says P Reed Maurer, president of International Alliances Limited, and a pharma industry watchers who has lived and worked in Japan since 1970.

In reality, top tier companies have ample cash to acquire product assets from outside Japan, the pace of new drug introductions is increasing, and there are more new drug ideas in Japan than there is funding to develop these “seeds” into proven drugs.

Why are prices reduced?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical